China Blood Products Industry Report, 2011-2012

Date: June 1, 2012
Pages: 97
Price:
US$ 2,300.00
License [?]:
Publisher: ResearchInChina
Report type: Strategic Report
Delivery: E-mail Delivery (PDF), Hard Copy Mail Delivery
ID: CA15CE21CE6EN
Leaflet:

Download PDF Leaflet

China Blood Products Industry Report, 2011-2012
Blood plasma serves as key raw material in blood product industry. In August 2011, the shut-down of 16 plasma collection stations in Guizhou province, China resulted in a YoY decline of 15% in plasma volume and further intensified the tight supply of raw material plasma. But when it comes to the lot release volume, the blood product output in China grew as high as 15.4% YoY in 2011, and the market size rose 22% YoY to around RMB11.6 billion. Additionally, in consideration of 12th Five-Year Plan for Doubling Blood Product Supply proposed by the Minister of the Ministry of Health at the end of 2011, the issuance of Notice of the Ministry of Health on Management of Plasma Collection Stations in early 2012, and the domestic market demand & supply, the blood product market size in China is expected to maintain a high growth rate of over 20% in the five years to come.

However, the low degree of industry concentration, the companies’ weak R&D capabilities, short supply of raw material plasma and low plasma utilization rate affect the development of Chinese blood product industry to some extent. The blood products released in overseas market divide into around 40 varieties, and the international blood product giants can extract about 15 varieties of blood products from plasma, while among Chinese companies, Beijing Tiantan Biological Products Co., Ltd. can produce at most 11 varieties from plasma. Moreover, Chinese blood product market is principally concentrated on human albumin and human immunoglobulin (pH4) for intravenous injection which pose low requirements on technologies. In 2011, the lot release volume of the two products made up 53.4% and 16.8% of the total release volume respectively.

Blood coagulation factor and thrombin products feature the largest demand gap in China, but there are less domestic supply and fewer producers. In 2011, the manufacturers of Human Coagulation Factor VIII in China just include Shanghai RAAS Blood Products, Green Cross China and Hualan Biological Engineering Inc., with lot release volume adding up to 350,000 bottles, and the producers of Human Prothrombin Complex are Hualan Biological Engineering Inc., Shanghai RAAS Blood Products and Shanghai Xinxing Medicine, with lot release volume totaling 200,000 bottles. Essentially, subsidiaries under China National Biotech Group and other Groups that possess production capacity and obtain governmental approvals in Coagulation Factor VIII and IX do not conduct production in recent years. With the intensifying contradiction between supply and demand, the government may launch intervention measures to enable the enterprises with the approval to restart the manufacturing of these products to raise overall supply of products of this sort.

Although taking such factors like home market demand into account, China has allowed the import of some blood products, but the imports are confined to human albumin and recombinant coagulation factor. Moreover, blood product manufacturing is a sector with no allowance for foreign capital. The imported human albumin almost makes up 50% market share, and the proportion reached 43.3% in 2011.

Following the tougher conflict between supply & demand and the loosening of policies in China, foreign brands quicken their pace of tapping into Chinese market. In May 2012, SFDA approved the release of Baxter’s ADVATE (Recombinant Human Coagulation Factor VIII for injection) in China which was another foreign brand of coagulation factor after the imported Bayer’s Recombinant Coagulation Factor VIII in 2007. Moreover, Pfizer is applying for quick approval program for its Recombinant Coagulation Factor IX (obtained from Wyeth).

The report resolves around the followings:
  • The plasma volume, distribution of plasma stations, market size and supply & demand of Chinese blood product industry;
  • Competition pattern, policy climate and import & export of Chinese blood product industry;
  • Market supply & demand and competitive landscape of 8 blood products such as human albumin, human immunoglobulin (pH4) for intravenous injection and coagulation factor, etc.
  • Status quo, operation, plasma collection station and product lot release volume of 9 Chinese blood product manufacturers.
1. PROFILE OF BLOOD PRODUCTS

1.1 Definition
1.2 Classification
1.3 Recombinant Blood Products
1.4 Industry Chain
1.5 Features

2. OVERVIEW OF CHINA BLOOD PRODUCTS INDUSTRY

2.1 Market Size
2.2 Development Status
2.3 Market Supply & Demand
  2.3.1 Supply
  2.3.2 Demand
2.4 Market Competition
2.5 Operating Environment
  2.5.1 International Market
  2.5.2 Policies
  2.5.3 Domestic Biopharmaceutical Market
2.6 Import & Export

3. BLOOD PRODUCT MARKET SEGMENTS IN CHINA

3.1 Human Albumin
  3.1.1 Supply & Demand
  3.1.2 Competition Pattern
  3.1.3 Prospects
3.2 Human Immunoglobulin (pH4) for Intravenous Injection
  3.2.1Supply & Demand
  3.2.2 Competition Pattern
3.3 Coagulation Factor
  3.3.1 Supply & Demand
  3.3.2 Competition Pattern
  3.3.3 Prospects
3.4 Hepatitis B Immunoglobulin
  3.4.1 Supply & Demand
  3.4.2 Competition Pattern
3.5 Human Immunoglobulin
  3.5.1 Supply & Demand
  3.5.2 Competition Pattern
3.6 Human Prothrombin Complex
  3.6.1 Supply & Demand
  3.6.2 Competition Pattern
3.7 Tetanus Immunoglobulin
  3.7.1 Supply & Demand
  3.7.2 Competition Pattern
3.8 Rabies Immunoglobulin
  3.8.1 Supply & Demand
  3.8.2 Competition Pattern

4. KEY MANUFACTURERS IN CHINA

4.1 Hualan Biological Engineering Inc.
  4.1.1 Profile
  4.1.2 Operation
  4.1.3 Revenue Structure
  4.1.4 Gross Margin
  4.1.5 Clients and Suppliers
  4.1.6 R&D and Investment
  4.1.7 Blood Products
4.2 Shanghai RAAS Blood Products Co., Ltd.
  4.2.1 Profile
  4.2.2 Operation
  4.2.3 Revenue Structure
  4.2.4 Gross Margin
  4.2.5 Clients and Suppliers
  4.2.6 R&D and Investment
4.3 Beijing Tiantan Biological Products Co., Ltd.
  4.3.1 Profile
  4.3.2 Operation
  4.3.3 Revenue Structure
  4.3.4 Gross Margin
  4.3.5 Clients and Suppliers
  4.3.6 Blood Products
4.4 China Biologic Products Inc.
  4.4.1 Profile
  4.4.2 Operation
  4.4.4 Cost Analysis
  4.4.5 Clients and Suppliers
  4.4.6 Shandong Taibang Biological Products Co., Ltd.
  4.4.7 Guiyang Qianfeng Biological Products Co., Ltd.
  4.4.8 Xi’an Hui Tian Blood Products Co., Ltd.
4.5 Jiangxi Boya Biopharmaceutical Co., Ltd.
  4.5.1 Profile
  4.5.2 Operation
  4.5.3 Revenue Structure
  4.5.4 Gross Margin
  4.5.5 Clients and Suppliers
  4.5.6 Output & Sales Volume and Price
  4.5.7 R&D and Investment
4.6 Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
  4.6.1 Profile
  4.6.2 Blood Products
4.7 CNBG Shanghai Institute of Biological Products
  4.7.1 Profile
  4.7.2 Blood Products
4.8 Shanxi Kangbao Biological Product Co., Ltd.
  4.8.1 Profile
  4.8.2 Blood Products
4.9 Green Cross
  4.9.1 Profile
  4.9.2 Blood Products

SELECTED CHARTS

Basic Components of Blood
Classification and Effects of Blood Products
Comparison between Gene Recombinant Blood Products and Traditional Blood Products
Categories and Comparison of Recombinant Blood Products in China and Worldwide
Blood Product Industry Chain
Blood Product Market Scale in China, 2003-2015E
Lot Release Volume of Blood Products (by Product) in China, 2007-2011
Product Structure of Blood Products in China (by Lot Release Volume), 2009-2011
Annual Plasma Volume in China, 2002-2011
Geographical Distribution of Plasma Collection Station Resources in China, by the End of 2011
Medical Insurance Coverage in Mainstream Blood Products in China
Comparison of Per Capita Usage of Blood Products between China and Developed Countries
Distribution of Plasma Collection Stations, Plasma Volume and Blood Products Revenue of Chinese Major Blood Product Manufacturers, 2011
Comparison among Blood Product Manufacturing Enterprises in China by Product Line
Blood Products in Overseas Countries
On-going Clinical Trial of New Indications Overseas
Global Blood Products Manufacturers
Major Policies Concerning Blood Products in China
Sales Value and Total Profit of Biological & Biochemical Product Industry in China, 2008-2011
Ratio of Domestic and Imported Human Albumin in China (by Lot Release Volume), 2007-2010
Market Share of Major Manufacturers of Human Albumin in China (by Lot Release Volume), 2007-2011
Comparison between China and USA by Consumption of Human Immunoglobulin (pH4) for Intravenous Injection, 2010
Lot Release Volume and Its Growth Rate of Human Immunoglobulin (pH4) for Intravenous Injection in China, 2007-2010
Prices of Human Immunoglobulin (pH4) for Intravenous Injection in China and Other Countries
Market Share of Major Manufacturers of Human Immunoglobulin (pH4) for Intravenous Injection in China (by Lot Release Volume), 2007-2011
Lot Release Volume and Its Growth Rate of Coagulation Factor VIII in China, 2008-2011
Market Share of Major Manufacturers of Coagulation Factor VIII in China (by Lot Release Volume), 2008-2011
Comparison between Human-derived Coagulation Factor VIII and Recombinant Coagulation Factor VIII
Lot Release Volume and Its Growth Rate of Hepatitis B Immunoglobulin in China, 2008-2011
Market Share of Major Manufacturers of Hepatitis B Immunoglobulin in China (by Lot Release Volume), 2008-2011
Lot Release Volume and Its Growth Rate of Human Immunoglobulin in China, 2008-2011
Market Share of Major Manufacturers of Human Immunoglobulin in China (by Lot Release Volume), 2008-2011
Lot Release Volume and Its Growth Rate of Human Prothrombin Complex in China, 2008-2011
Market Share of Manufacturers of Human Prothrombin Complex in China (by Release Volume), 2008-2011
Lot Release Volume and Its Growth Rate of Tetanus Immunoglobulin in China, 2008-2011
Market Share of Major Manufacturers of Tetanus Immunoglobulin in China (by Release Volume), 2008-2011
Lot Release Volume and Its Growth Rate of Human Rabies Immunoglobulin in China, 2008-2011
Market Share of Major Manufacturers of Human Rabies Immunoglobulin in China (by Release Volume), 2008-2011
Revenue and Total Profit of Hualan Biological, 2007-2012
Revenue Breakdown of Hualan Biological by Industry, 2007-2011
Revenue Structure of Hualan Biological by Industry, 2007-2011
Revenue Breakdown of Hualan Biological by Product, 2007-2011
Revenue Structure of Hualan Biological by Product, 2007-2011
Revenue Breakdown of Hualan Biological by Region, 2007-2011
Revenue Structure of Hualan Biological by Region, 2007-2011
Gross Margin of Hualan Biological by Industry, 2007-2011
Gross Margin of Hualan Biological by Product, 2007-2011
Hualan Biological’s Revenue from Top 5 Clients and % of Total Revenue, 2007-2011
Hualan Biological’s Procurement from Top 5 Suppliers and % of Total Procurement,2007-2011
R&D Costs and % of Total Revenue of Hualan Biological, 2007-2011
Distribution of Plasma Collection Stations of Hualan Biological, 2011
Lot Release Volume of Blood Products of Hualan Biological, 2008-2011
Proportion of Blood Products Release Volume of Hualan Biological, 2008-2011
Revenue and Gross Margin of Blood Products of Hualan Biological, 2007-2011
Revenue and Gross Margin of Blood Products of Hualan Biological (by Product), 2007-2011
Distribution of Plasma Collection Stations of Shanghai RAAS Blood Products Co., Ltd, by the End of 2011
Revenue and Profit of Shanghai RAAS, 2007-2012
Lot Release Volume of Blood Products of Shanghai RAAS Blood Products Co., Ltd, 2007-2011
Proportion of Blood Products Release Volume of Shanghai RAAS, 2007-2011
Revenue Breakdown of Shanghai RAAS by Product, 2007-2011
Revenue Structure of Shanghai RAAS by Product, 2007-2011
Revenue Breakdown of Shanghai RAAS by Region, 2007-2011
Revenue Structure of Shanghai RAAS by Region, 2007-2011
Gross Margin of Shanghai RAAS by Product, 2007-2011
Shanghai RAAS’s Revenue from Top 5 Clients and % of Total Revenue,2007-2011
Name List and Revenue Contribution of Shanghai RAAS’s Top 5 Clients, 2011
Shanghai RAAS’s Procurement from Top 5 Suppliers and % of Total Procurement,2007-2011
R&D Costs and % of Total Revenue of Shanghai RAAS,2007-2011
Revenue and Net Income of Tiantan Biological’s Major Joint-stock Companies, 2011
Revenue and Total Profit of Beijing Tiantan Biological, 2007-2012
Revenue Breakdown of Beijing Tiantan Biological by Industry, 2007-2011
Revenue Breakdown of Beijing Tiantan Biological by Region, 2007-2011
Gross Margin of Beijing Tiantan Biological by Industry, 2007-2011
Beijing Tiantan Biological’s Procurement from Top 5 Suppliers and % of Total Procurement,
2007-2011
Beijing Tiantan Biological’s Revenue from Top 5 Clients and % of Total Revenue, 2007-2011
Name List and Revenue Contribution of Top 5 Clients of Beijing Tiantan Biological’s Top 5 Clients, 2011
Distribution of Plasma Collection Stations of Beijing Tiantan Biological, by the End of 2011
Revenue and Gross Margin of Blood Products of Beijing Tiantan Biological, 2007-2011
Lot Release Volume of Blood Products of Chengdu Rongsheng, 2007-2011
Equity Structure of China Biologic Product Inc.
Revenue and Operating Income of China Biologic Products Inc., 2007-2011
Revenue Structure of China Biologic Products Inc. by Product, 2008-2011
Plasma Collection Costs of China Biologic Products Inc., 2008-2011
China Biologic Products Inc.’s Revenue from Top 5 Clients and % of Total Revenue, 2008-2011
Name List and Revenue Contribution of China Biologic Products Inc.’s Top 5 Clients, 2011
Name List and Procurement Contribution of China Biologic Products Inc.’s Top 10 Suppliers, 2011
Lot Release Volume of Blood Products of Shandong Taibang, 2007-2011
Lot Release Volume of Blood Products of Guiyang Qianfeng, 2007-2011
Lot Release Volume of Blood Products of Xi’an Hui Tian, 2007-2011
Plasma Inventory, Plasma Collection Amount and Plasma Volume of Boya Biopharmaceutical, 2009-2011
Distribution and Collection Amount of Plasma Collection Stations of Boya Biopharmaceutical, 2009-2011
Revenue and Profit of Boya Biopharmaceutical, 2009-2012
Revenue Breakdown of Boya Biopharmaceutical by Product, 2009-2011
Revenue Structure of Boya Biopharmaceutical by Product, 2009-2011
Lot Release Volume of Blood Products of Boya Biopharmaceutical, 2007-2011
Revenue Breakdown of Boya Biopharmaceutical by Region, 2009-2011
Revenue Structure of Boya Biopharmaceutical by Region, 2009-2011
Gross Margin of Boya Biopharmaceutical by Product, 2009-2011
Boya Biopharmaceutical’s Revenue from Top 5 Clients and % of Total Revenue, 2009-2011
Name List and Revenue Contribution of Boya Biopharmaceutical’s Top 5 Clients, 2011
Boya Biopharmaceutical’s Procurement from Top 5 Suppliers and % of Total Procurement,2009-2011
Name List and Procurement Contribution of Boya Biopharmaceutical’s Top 5 Suppliers, 2011
Output & Sales Volume and Inventory of Boya Biopharmaceutical by Product, 2009-2011
Prices of Boya Biopharmaceutical by Product, 2009-2011
R&D Costs and % of Total Revenue of Boya Biopharmaceutical, 2009-2011
Blood Product R&D Projects and Progress of Boya Biopharmaceutical, by the End of 2011
Distribution of Plasma Collection Stations of Yuanda Shuyang, by the End of 2011
Lot Release Volume of Blood Products of Yuanda Shuyang, 2007-2011
Lot Release Volume of Blood Products of CNBG Shanghai Institute of Biological Products, 2007-2011
Distribution of Plasma Collection Stations of CNBG Shanghai Institute of Biological Products, by the End of 2011
Distribution of Plasma Collection Stations of Shanxi Kangbao, by the End of 2011
Lot Release Volume of Blood Products of Shanxi Kangbao, 2007-2011
Distribution of Plasma Collection Stations of Green Cross, by the End of 2011
Lot Release Volume of Blood Products of Green Cross, 2007-2011
Skip to top


Ask Your Question

China Blood Products Industry Report, 2011-2012
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: